Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high‐dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant‐ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

[1]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[2]  A. Krishnan,et al.  Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Barlogie,et al.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. , 2014, The Lancet. Oncology.

[5]  H. Goldschmidt,et al.  IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.

[6]  Ocn,et al.  Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM) , 2013 .

[7]  L. Fernyhough,et al.  Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma , 2013 .

[8]  H. Goldschmidt,et al.  Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies , 2013 .

[9]  M. Boccadoro,et al.  A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients , 2013 .

[10]  M. Boccadoro,et al.  A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients , 2013 .

[11]  M. Dimopoulos,et al.  Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) , 2013 .

[12]  D. Esseltine,et al.  Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[14]  A. Lesokhin,et al.  Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center , 2013, Bone Marrow Transplantation.

[15]  F. Prósper,et al.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.

[16]  M. Boccadoro,et al.  Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. , 2013 .

[17]  P. Sonneveld,et al.  Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials , 2013, Haematologica.

[18]  D. Esseltine,et al.  Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Braylan,et al.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study , 2013, Leukemia & lymphoma.

[20]  H. Einsele,et al.  Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients , 2012 .

[21]  J. Miguel,et al.  Haematological cancer: Redefining myeloma , 2012, Nature Reviews Clinical Oncology.

[22]  M. Kersten,et al.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Flinn,et al.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.

[24]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[25]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[26]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[27]  R. Fonseca,et al.  A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma , 2012, British journal of haematology.

[28]  D. Hose,et al.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.

[29]  G. Morgan,et al.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.

[30]  D. Reece.  Posttransplantation maintenance therapy and optimal frontline therapy in myeloma. , 2011, Hematology. American Society of Hematology. Education Program.

[31]  G. Morgan,et al.  Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.

[32]  P. Fayers,et al.  Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.

[33]  P. L. Bergsagel,et al.  Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial , 2011, American journal of hematology.

[34]  J. Besalduch,et al.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. , 2011, Blood.

[35]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[36]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[37]  A. Órfão,et al.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[39]  M. Bua,et al.  High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma , 2011, Bone Marrow Transplantation.

[40]  J. Yagüe,et al.  Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents , 2011, Haematologica.

[41]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[42]  M. Boccadoro,et al.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.

[43]  R. Fonseca,et al.  Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial , 2010 .

[44]  M. Mohty,et al.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Miguel,et al.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.

[46]  J. Szer,et al.  Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy. , 2010 .

[47]  P. L. Bergsagel,et al.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. , 2010, Blood.

[48]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  P. Sonneveld,et al.  A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. , 2010, Blood.

[50]  M. Boccadoro,et al.  Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[52]  N. Schmitz,et al.  Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). , 2009 .

[53]  R. Greil,et al.  Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. , 2009 .

[54]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  K. Anderson,et al.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. , 2009, Blood.

[56]  B. Pégourié,et al.  Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Horsman,et al.  Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. , 2009, Blood.

[58]  B. Djulbegovic,et al.  Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis , 2009 .

[59]  A. Zannettino,et al.  Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment , 2009, Internal medicine journal.

[60]  R. Greil,et al.  Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. , 2009, Blood.

[61]  P. Moreau.  Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma , 2009, Bone Marrow Transplantation.

[62]  P. L. Bergsagel,et al.  Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial , 2009, Leukemia.

[63]  B. Djulbegovic,et al.  Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. , 2009, Journal of the National Cancer Institute.

[64]  J. S. San Miguel,et al.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.

[65]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[66]  J. Leonard,et al.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[67]  D. Esseltine,et al.  Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up , 2008, British journal of haematology.

[68]  U. Mellqvist,et al.  Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma , 2008, Cancer.

[69]  H. van de Velde,et al.  Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.

[70]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[71]  M. Baccarani,et al.  Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Morgan,et al.  Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.

[73]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[74]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[75]  N. Munshi,et al.  High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[76]  A. Schwarer,et al.  Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. , 2007, Cytotherapy.

[77]  P. Sonneveld,et al.  Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.

[78]  R. Wieser,et al.  Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion , 2007, Leukemia.

[79]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[80]  J. Bourhis,et al.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.

[81]  D. Dingli,et al.  Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. , 2006, Clinical lymphoma & myeloma.

[82]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  G. Morgan,et al.  The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis , 2006, Leukemia & lymphoma.

[84]  B. Barlogie,et al.  Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) , 2006 .

[85]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[86]  S. Chevret,et al.  A Meta-Analysis on Data From 575 Patients With Multiple Myeloma Randomly Assigned to Either High-Dose Therapy or Conventional Therapy , 2005, Medicine.

[87]  M. Baccarani,et al.  Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. , 2005, Blood.

[88]  C. Kyriakou,et al.  Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma , 2005, British journal of haematology.

[89]  D. Esseltine,et al.  PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma , 2005, British journal of haematology.

[90]  S. Jagannath,et al.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma , 2005, British journal of haematology.

[91]  P. Marlton,et al.  Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. , 2004, The hematology journal : the official journal of the European Haematology Association.

[92]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[93]  Robert A Kyle,et al.  Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[95]  A. Palumbo,et al.  Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  P. Ravaud,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.

[97]  D. Goldstein,et al.  Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma , 1997, British journal of haematology.

[98]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[99]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[100]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[101]  N. Ifrah,et al.  Double-intensive therapy in high-risk multiple myeloma. , 1992, Blood.

[102]  D. Weisenburger,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. , 1989, Blood.